Quadrature Capital Ltd Sells 41,941 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Quadrature Capital Ltd reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 92.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,470 shares of the medical research company's stock after selling 41,941 shares during the period. Quadrature Capital Ltd's holdings in Charles River Laboratories International were worth $683,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of CRL. Tortoise Investment Management LLC raised its holdings in shares of Charles River Laboratories International by 77.0% in the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock valued at $27,000 after purchasing an additional 57 shares during the last quarter. Wolff Wiese Magana LLC bought a new stake in Charles River Laboratories International in the 3rd quarter worth about $32,000. Assetmark Inc. increased its stake in Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock valued at $37,000 after buying an additional 173 shares during the last quarter. Whittier Trust Co. of Nevada Inc. lifted its position in shares of Charles River Laboratories International by 219.3% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company's stock worth $58,000 after buying an additional 193 shares in the last quarter. Finally, Covestor Ltd boosted its stake in shares of Charles River Laboratories International by 40.9% in the 3rd quarter. Covestor Ltd now owns 327 shares of the medical research company's stock worth $65,000 after buying an additional 95 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

CRL stock traded up $9.94 during mid-day trading on Monday, hitting $201.75. 629,818 shares of the stock were exchanged, compared to its average volume of 619,012. The business has a fifty day moving average price of $194.10 and a 200 day moving average price of $203.67. Charles River Laboratories International, Inc. has a 12 month low of $176.48 and a 12 month high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The stock has a market capitalization of $10.32 billion, a price-to-earnings ratio of 24.01, a PEG ratio of 4.95 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts' consensus estimates of $2.43 by $0.16. The business had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business's quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the business earned $2.72 earnings per share. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CRL. Redburn Atlantic started coverage on Charles River Laboratories International in a research report on Monday, October 14th. They set a "sell" rating and a $151.00 price target on the stock. StockNews.com downgraded Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Thursday, November 7th. TD Cowen lifted their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research report on Monday, November 11th. Evercore ISI increased their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an "in-line" rating in a report on Thursday, November 7th. Finally, CLSA lowered Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 target price for the company. in a report on Monday, November 18th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $214.38.

Insiders Place Their Bets

In other news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now owns 12,386 shares in the company, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).